Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.

about

Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.

Item

http://www.wikidata.org/entity/Q41233808

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Molecular dissection of effect ...... to anti-EGFR antibody therapy.

@en

type

Item

label

Molecular dissection of effect ...... to anti-EGFR antibody therapy.

@en

prefLabel

Molecular dissection of effect ...... to anti-EGFR antibody therapy.

@en

P1476

Molecular dissection of effect ...... to anti-EGFR antibody therapy.

@en

P2093

Andre Mueller

http://www.w3.org/2001/XMLSchema#string

Andreas Paul

http://www.w3.org/2001/XMLSchema#string

Anna Even

http://www.w3.org/2001/XMLSchema#string

Frank Breitenbuecher

http://www.w3.org/2001/XMLSchema#string

Jeannette Phasue

http://www.w3.org/2001/XMLSchema#string

Johannes Meiler

http://www.w3.org/2001/XMLSchema#string

Karl Worm

http://www.w3.org/2001/XMLSchema#string

Kurt Werner Schmid

http://www.w3.org/2001/XMLSchema#string

Martin Schuler

http://www.w3.org/2001/XMLSchema#string

Michael Pogorzelski

http://www.w3.org/2001/XMLSchema#string

P2860

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

Improved overall survival in melanoma with combined dabrafenib and trametinib.

P304

45898-45917

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.17438

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-04-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28507280

http://www.w3.org/2001/XMLSchema#string

P932

5542236

http://www.w3.org/2001/XMLSchema#string